Home › Neuroendocrine Tumors › Georgia › Atlanta
Neuroendocrine Tumors clinical trials in Atlanta, GA
5 studies for Neuroendocrine Tumors are looking for participants at sites in and around Atlanta (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
RecruitingPhase 3
- Winshop Cancer Institute - Emory University, Atlanta
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RecruitingPhase 1/2
- Crinetics Study Site, Atlanta
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
RecruitingPhase 1/2
- Emory University, Atlanta
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Atlanta
Neuroendocrine Tumors trials in other cities
- Philadelphia, PA11 studies
- Washington, DC11 studies
- Rochester, MN9 studies
- Houston, TX8 studies
- Chicago, IL7 studies
- Columbus, OH7 studies
- St. Louis, MO7 studies
- Detroit, MI7 studies
- Cleveland, OH7 studies
- Salt Lake City, UT7 studies
- Dallas, TX6 studies
- Charlottesville, VA6 studies
Other studies in Atlanta
- Cancer (all types)49 studies
- Non-Small Cell Lung Cancer47 studies
- Multiple Myeloma42 studies
- Breast Cancer41 studies
- Prostate Cancer33 studies
- Acute Myeloid Leukemia31 studies
- Ovarian Cancer29 studies
- Colorectal Cancer29 studies
- Lung Cancer29 studies
- Metastatic Cancer28 studies
- Major Depressive Disorder25 studies
- Heart Failure25 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.